RECLAST
Total Payments
$12,162
Transactions
3
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $11,034 | 2 | 1 |
| 2017 | $1,128 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,150 | 2 | 99.9% |
| Food and Beverage | $12.30 | 1 | 0.1% |
Payments by Type
Research
$12,150
2 transactions
General
$12.30
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RANDOMIZED DOUBLE BLIND SAFETY AND EFFICACY TRIAL WITH INTRAVENOUS ZOLEDRONIC ACID FOR THE TREATMENT OF PAGETS DISEASE OF BONE USING RISEDRONATE AS A COMPARATOR | Novartis Pharmaceuticals Corporation | $11,022 | 0 |
| A BIOLOGY STUDY OF THE MECHANISMS OF RESISTANCE TO TARGETED THERAPIES PLEASE NOTE THAT THIS IS A NON TREATMENT PROTOCOL | Novartis Pharmaceuticals Corporation | $1,128 | 0 |
Top Doctors Receiving Payments for RECLAST
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $12,150 | 2 |
| , MD | Medical Oncology | E Setauket, NY | $12.30 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $12,162
- Total Doctors 1
- Transactions 3
About RECLAST
RECLAST is a drug associated with $12,162 in payments to 1 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $11,034 was paid across 2 transactions to 1 doctors.
The most common payment nature for RECLAST is "Unspecified" ($12,150, 99.9% of total).
RECLAST is associated with 2 research studies, including "RANDOMIZED DOUBLE BLIND SAFETY AND EFFICACY TRIAL WITH INTRAVENOUS ZOLEDRONIC ACID FOR THE TREATMENT OF PAGETS DISEASE OF BONE USING RISEDRONATE AS A COMPARATOR" ($11,022).